Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Adrafinil
Adrafinil (2-benzhydrylsulfinyl-N-hydroxyacetamide) is a synthetic eugeroic of the benzhydrylsulfinylacetamide class. It is a prodrug of modafinil — it converts to modafinil in the liver, the form that actually acts in the brain. Modafinil blocks dopamine reuptake, raising dopamine levels and promoting wakefulness.[1]
Adrafinil (2-benzhydrylsulfinyl-N-hydroxyacetamide) is a synthetic eugeroic of the benzhydrylsulfinylacetamide class. It is a prodrug of modafinil, converted to its active form in the liver. Adrafinil's effects are mediated by DAT blockade, producing wakefulness through increased extracellular dopamine.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Adrafinil was identified in 1974 in France and launched commercially as Olmifon in 1985, prescribed for narcolepsy and age-related vigilance decline.[2] Modafinil proved clinically superior — it worked directly without the liver conversion step — and the manufacturer voluntarily withdrew Olmifon in 2011.[3] It now circulates as an unregulated supplement in several jurisdictions.[4]
Subjective effects include sustained wakefulness, cognitive clarity, mood elevation, and increased motivation. The experience is one of quiet alertness — a gradual, clean arousal without the jittery push or euphoria of amphetamine-class stimulants.[5] Insomnia, headache, nausea, and mild anxiety are common unsought effects.[6]
Dependence liability is minimal and acute toxicity is low.[5][7] The dominant chronic concern is the liver — adrafinil requires extra hepatic processing compared to modafinil, and one case of persistent involuntary facial movements after chronic use has been documented.[8] No dedicated clinical trials exist for adrafinil; the evidence base rests almost entirely on modafinil research and assumed equivalence after conversion.[9]
History[edit]
Discovery
Adrafinil was identified in 1974 by researchers at Laboratoire Louis Lafon in France during systematic study of benzhydryl sulfoxide compounds.[2] Modafinil was recognized as adrafinil's primary active metabolite two years later.[10] Michel Jouvet, the neurologist who discovered REM sleep, began prescribing adrafinil to narcoleptic patients around 1977 but switched to modafinil directly by 1983 after inconsistent results.[2]
Clinical and commercial history
Adrafinil launched in France on 19 September 1985 as Olmifon, indicated for narcolepsy and vigilance deficits in the elderly.[2][3] Modafinil received French registration in 1992 and proved superior — it worked directly without the liver conversion step. The manufacturer voluntarily discontinued Olmifon in September 2011, citing an unfavorable risk–benefit ratio.[3][2]
Modern era
After discontinuation, adrafinil re-emerged in the nootropic supplement market, particularly in jurisdictions where it remains unregulated.[4] It has been confirmed in US products marketed as dietary supplements.[4] The compound now occupies a regulatory paradox: a discontinued pharmaceutical sold over the counter while its active metabolite is controlled or prescription-only in most of the developed world.[11]
The class name "eugeroic" — from the Greek eu (good) and gregor (wakening) — was coined for this new category of wakefulness-promoting agents, of which adrafinil is a founding member.[12] Both adrafinil and modafinil were banned in competitive sport by the World Anti-Doping Agency in 2004 under S6 (Stimulants), prohibited in-competition only.[13][14]
Chemistry[edit]
Structural class
Adrafinil belongs to the benzhydrylsulfinylacetamide family — compounds built around a diphenylmethane core linked to a sulfinyl group. What distinguishes it from its active metabolite modafinil is a hydroxamic acid group where modafinil carries a simpler acetamide. The liver cleaves this group during metabolism, yielding modafinil and an inactive byproduct.[6][15]
Molecular identity
| Molecular formula | C₁₅H₁₅NO₃S |
| Molecular weight | 289.35 g/mol |
The molecule connects a diphenylmethane group through a sulfinyl bridge (S=O) to an N-hydroxyacetamide chain.[16][17] Both adrafinil and modafinil emerged from systematic study of benzhydryl sulfoxide compounds at Laboratoire Louis Lafon in the 1970s.[2]
Pharmacology[edit]
Mechanism of action
Adrafinil is a prodrug — its effects require liver conversion to modafinil before it acts in the brain.[6][15] Whether it has direct pharmacological activity of its own remains unknown.[12][18] Modafinil blocks the DAT, raising dopamine levels in arousal circuits and promoting wakefulness.[1]
Unlike amphetamine-class stimulants, modafinil blocks dopamine reuptake without triggering direct dopamine release.[5][19] This distinction explains its lower reinforcement potential — blockade produces a gentler, slower rise in dopamine than release does. It also activates orexin, histamine, and norepinephrine wakefulness circuits.[6][20][5]
Pharmacokinetics
The liver converts adrafinil to modafinil (active) and modafinilic acid (inactive).[6][15] Modafinil reaches peak blood levels 2–4 hours after oral dosing and has a half-life of approximately 12–15 hours.[21] For adrafinil, onset is slower and peak modafinil levels may be lower, because the conversion step takes time and is incomplete.
Neuroscience[edit]
Where it acts
Modafinil — the active form of adrafinil — promotes wakefulness through dopaminergic circuits connecting the midbrain to the prefrontal cortex.[19] It selectively engages cortical arousal pathways rather than the brain's reward circuits. This selectivity explains why it produces alertness without the strong euphoria or abuse liability of amphetamines.[19]
Why it matters
Modafinil's profile demonstrates that wakefulness and reward can be pharmacologically separated. Dopamine rises in reward regions of the brain, but not enough in magnitude or speed to generate strong pleasure or compulsive use.[19][5] The result is motivation and alertness without the pull toward repeated use that defines amphetamines.
Whether adrafinil has pharmacological activity independent of its conversion to modafinil remains unknown — it has been classified as an alpha-1 adrenergic agonist, but no binding data exist to confirm this.[12] One case of persistent involuntary facial movements after chronic use[8] raises the possibility of dopaminergic sensitization, but no systematic follow-up exists. The long-term neural effects of chronic use are uncharacterized.
Subjective Effects[edit]
Adrafinil's effects unfold gradually as the liver converts it to modafinil. The experience is quiet, sustained alertness — a clean wakefulness that builds over an hour or two rather than arriving abruptly. There is no jittery push and no pronounced euphoria.
The experience is qualitatively identical to Modafinil but typically slower to arrive and potentially less intense due to the conversion step.[5][19] Compared to amphetamine-class stimulants, adrafinil produces notably less euphoria and anxiety at equivalent wake-promoting doses. Individual variation is substantial, shaped by liver activity, sleep debt, and prior stimulant tolerance.
Identified in 1974 at Laboratoire Louis Lafon in France, adrafinil was launched commercially as Olmifon in 1985 for narcolepsy and age-related vigilance deficits.[2] The manufacturer voluntarily discontinued it in 2011, citing an unfavorable risk–benefit ratio relative to modafinil.[3] It now circulates as an unregulated nootropic supplement in several jurisdictions.[4]
Subjective effects include sustained wakefulness, cognitive clarity, mood elevation, and increased motivation. The experience is one of quiet alertness — a gradual, clean arousal without the jittery push or euphoria characteristic of amphetamine-class stimulants.[5] Insomnia, headache, nausea, and mild anxiety are common unsought effects.[6]
Dependence liability is minimal, and acute toxicity is low in animal models.[7][5] The principal chronic concern is hepatic — adrafinil requires additional liver processing compared to modafinil, and one case of persistent involuntary facial movements has been reported after chronic use.[8] No dedicated clinical trials exist for adrafinil; the evidence base rests almost entirely on modafinil research and the assumption of equivalence after conversion.[9]
History[edit]
Discovery
Adrafinil (CRL-40028) was identified in 1974 by researchers at Laboratoire Louis Lafon in France during systematic investigation of benzhydryl sulfoxide compounds.[2] Two years later, modafinil was recognized as adrafinil's primary active metabolite.[10] Michel Jouvet, the French neurologist who discovered REM sleep, began prescribing adrafinil to narcoleptic patients around 1977–1978, but results were inconsistent; by 1983 he had shifted to prescribing modafinil directly.[2]
Clinical and commercial history
Adrafinil launched in France on 19 September 1985 under the brand name Olmifon, indicated for narcolepsy and vigilance deficits in the elderly.[2][3] Modafinil received French registration in 1992 and proved clinically superior — direct bioavailability eliminated the need for hepatic prodrug conversion. Cephalon Inc. acquired Lafon in 2001[2] and voluntarily discontinued Olmifon in September 2011, citing an unfavorable risk–benefit ratio.[3]
Modern era
Following discontinuation, adrafinil re-emerged in the nootropic supplement market, particularly in jurisdictions where it remains unregulated.[4] Analytical studies have confirmed its presence in products marketed as dietary supplements in the United States.[4] The compound occupies a regulatory paradox: a discontinued pharmaceutical circulating as an unscheduled supplement while its active metabolite remains a controlled or prescription substance in most of the developed world.[11]
The class name "eugeroic" — from the Greek eu (good) and gregor (wakening) — was coined to describe this new category of wakefulness-promoting agents, of which adrafinil is a founding member.[12] Both adrafinil and modafinil were banned in competitive sport by the World Anti-Doping Agency in 2004 under category S6 (Stimulants), prohibited in-competition only.[13][14]
Chemistry[edit]
Structural class
Adrafinil belongs to the benzhydrylsulfinylacetamide family — a group of compounds built around a diphenylmethane (benzhydryl) core linked to a sulfinyl group. What distinguishes adrafinil from its active metabolite modafinil is a hydroxamic acid (N-hydroxyacetamide) group where modafinil carries a simple acetamide. This hydroxamic acid group is cleaved during liver metabolism, yielding modafinil and the inactive byproduct modafinilic acid.[6][15]
Both adrafinil and modafinil emerged from systematic investigation of benzhydryl sulfoxide compounds at Laboratoire Louis Lafon during the 1970s.[2]
Molecular identity
| Molecular formula | C₁₅H₁₅NO₃S |
| Molecular weight | 289.35 g/mol |
The molecule consists of a diphenylmethane group connected through a sulfinyl bridge (S=O) to an N-hydroxyacetamide chain. The sulfinyl group links the lipophilic benzhydryl portion to the polar hydroxamic acid end.[16][17]
Stereochemistry
The sulfur atom of the sulfinyl group is a chirality center, giving adrafinil two mirror-image forms (enantiomers). The compound is used as a racemic mixture containing both.[18][19]
Whether the two enantiomers differ in pharmacological activity is unknown — a notable gap, given that modafinil's R-enantiomer (armodafinil) has a longer half-life and has been developed as a separate pharmaceutical product.[20]
Physical properties
Adrafinil is a white crystalline solid with limited water solubility. Published melting points conflict between vendor sources (140–142°C vs 159–160°C), and no primary analytical study has resolved the discrepancy.[7] NMR characterization has been published,[21][22] but most physical property data derive from chemical suppliers rather than peer-reviewed sources.
Pharmacology[edit]
Mechanism of action
Adrafinil is pharmacologically inactive or weakly active on its own — it functions as a prodrug, requiring liver conversion to modafinil before producing its primary effects.[6][15]
The parent compound has been classified as an alpha-1 adrenergic receptor agonist based on early pharmacological work showing that adrafinil could not antagonize yohimbine-induced toxicity in mice.[17][23] This classification remains a working hypothesis — no binding affinity data for adrafinil at any receptor have been published, and reviews have acknowledged that adrafinil's direct mechanisms "are still unknown".[12][24]
Once converted, modafinil promotes wakefulness primarily through DAT (DAT) blockade. PET imaging in healthy humans shows that modafinil at 200–400 mg occupies 47–70% of DAT in the caudate, putamen, and nucleus accumbens, increasing extracellular dopamine.[1] Wake-promoting potency correlates with DAT affinity rather than NET affinity.[25]
Unlike amphetamine-class stimulants, modafinil does not cause direct monoamine release — its mechanism is reuptake blockade only, which accounts for its lower reinforcement potential.[5][26] Secondary effects include activation of orexin/hypocretin, histamine, and norepinephrine pathways, along with increased glutamate and decreased GABA in cortical regions.[6][27][5]
Pharmacokinetics
Adrafinil is converted in the liver to modafinil (active) and modafinilic acid (inactive).[6][15] A human self-administration study confirmed this conversion: after a single 200 mg oral dose, both adrafinil and modafinil were detectable in hair at 10 days.[15]
No human pharmacokinetic parameters — peak concentration, bioavailability, or half-life — have been published for adrafinil as parent compound. All human data derive from modafinil studies.[20]
Modafinil reaches peak plasma levels 2–4 hours after oral dosing, with an elimination half-life of approximately 12–15 hours. Steady state is achieved within 2–4 days of repeated dosing. It is approximately 60% protein-bound and primarily eliminated through the kidneys, with less than 10% excreted unchanged.[20] Elimination is slowed in liver impairment, kidney impairment, and elderly patients.[20]
For adrafinil specifically, onset is delayed and peak modafinil concentrations may be lower than with direct modafinil dosing due to the conversion step.
Neuroscience[edit]
Where it acts
Adrafinil's wakefulness-promoting effects, mediated through modafinil, arise from dopaminergic activation in specific arousal circuits. The ventral tegmental area projections to the prefrontal cortex and the ventral periaqueductal gray dopaminergic neurons are key substrates for wake promotion.[26] Modafinil preferentially engages these cortical arousal pathways rather than producing robust reward signaling in the nucleus accumbens — a selectivity that accounts for its lower abuse liability compared to amphetamines.[26]
Beyond dopamine, modafinil recruits orexin/hypocretin neurons in the lateral hypothalamus, histaminergic neurons in the tuberomammillary nucleus, and noradrenergic neurons in the locus coeruleus.[27][5] This multi-system engagement produces sustained alertness without the sympathetic overdrive characteristic of pure dopaminergic stimulants.
Why it matters
Modafinil's pharmacological profile offers a natural test of the distinction between "wanting" (incentive salience, driven by mesolimbic dopamine) and "liking" (hedonic impact). DAT blockade elevates dopamine in the nucleus accumbens, yet the magnitude and kinetics are insufficient to generate strong euphoria or hedonic reinforcement.[26][5] This dissociation — wakefulness and motivation without proportional pleasure — makes adrafinil/modafinil an informative case for understanding how arousal and reward can be pharmacologically separated.
Several fundamental questions remain unanswered. Whether adrafinil has pharmacological activity independent of its conversion to modafinil is unknown — the alpha-1 adrenergic classification suggests direct effects, but no binding data exist. The long-term neural consequences of chronic use are uncharacterized; one case of persistent involuntary facial movement[8] implicates dopaminergic sensitization, but no systematic studies have followed.
Subjective Effects[edit]
Adrafinil's experiential character is shaped by its prodrug nature: the onset unfolds gradually as hepatic conversion to modafinil proceeds, producing a slow-building wakefulness rather than abrupt stimulation. The quality of arousal is characteristically clean — sustained alertness without prominent euphoria, sympathetic drive, or psychomotor agitation. Individual variation is substantial, governed by liver enzyme activity, prior stimulant tolerance, sleep debt, and concurrent medications.
Relative to Modafinil, the experience is qualitatively identical but temporally delayed and potentially attenuated due to incomplete first-pass conversion. Compared to amphetamine-class stimulants, adrafinil produces notably less euphoria and less anxiety at equivalent wake-promoting doses, consistent with modafinil's reuptake-blockade-only mechanism.[5][26]
Effect Grid
Sustained wakefulness for 4–6 hours with clear focus enhancement and motivation. Cognitive clarity is the dominant quality — tasks feel easier to initiate and maintain. Memory updating shows the most consistent improvement based on modafinil meta-analytic data (SMD = 0.28). Thought acceleration may be subtly present. The experience resembles a productive, unremarkable state of heightened alertness rather than overt stimulation.
Mild appetite suppression is typical. Headache occurs in a substantial minority (up to 34% in modafinil clinical trials). Nausea is possible. Slight elevation in heart rate may be noticed by sensitive individuals. Dehydration sensation is occasionally reported.
Total duration is approximately 6–10 hours. Sleep disruption is likely if dosed in the afternoon. The slow onset means planning around the 1–2 hour conversion delay is important for timing peak effects with demanding work.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Appetite suppression · Pupil dilation · Nausea · Dry mouth · Heart rate perception changes · Restlessness · Dizziness · Dehydration sensation · Vomiting
Heart rate perception changes · Restlessness · Dizziness · Dehydration sensation · Vomiting
Information processing enhancement · Thought organization
Timeline
Gradual awareness of increasing alertness as hepatic conversion to modafinil begins. Effects are subtle — drowsiness lifts slowly rather than stimulation arriving. Most users notice little during this phase under rested conditions.
Progressive sharpening of focus and wakefulness as modafinil plasma levels rise. Mental clarity increases noticeably. The transition is smooth — there is no abrupt gear-shift characteristic of direct-acting stimulants.
Sustained plateau of wakefulness and cognitive clarity. Focus enhancement and motivation are most prominent. The quality is characteristically clean — alertness without agitation or euphoria.
Gradual reduction in stimulation without a sharp crash. Wakefulness fades smoothly as modafinil plasma levels decline. Concentration returns to near-baseline.
Residual mild alertness or difficulty initiating sleep. Lingering appetite suppression is occasionally reported. Some users experience subtle cognitive clarity persisting below the threshold of active stimulation.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- 10.5 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- modafinil · armodafinil · benzhydryl class nootropics
Toxicity
Acute toxicity is low.[7] Common adverse effects — derived from modafinil clinical data — include headache, nausea, nervousness, insomnia, diarrhea, dry mouth, and elevated blood pressure and heart rate.[6]
Heart and circulation
Elevated heart rate and blood pressure are documented at clinical doses.[6] Cardiovascular risk is lower than with cocaine, desipramine, and bupropion at equivalent doses in animal models.[22]
Liver
Modafinil is rated an unlikely cause of clinically apparent liver injury. In a US study of 899 drug-induced liver injury cases, none were attributed to modafinil, and liver enzyme elevations above three times normal occurred in under 1% of patients in safety trials.[9]
Adrafinil requires additional liver processing compared to taking modafinil directly. No primary literature documents adrafinil-specific liver injury, but liver enzyme monitoring is recommended for regular use.safety citation needed
Movement disorders
One documented case describes persistent involuntary facial movements — uncontrolled repetitive movements of the mouth and jaw — following chronic adrafinil use.[8] The movements did not resolve after four months off the drug and required treatment with a dopamine-depleting medication. Neurologically vulnerable individuals, including the elderly, appear at higher risk.citation needed
Skin reactions
Rare severe skin reactions — including blistering rashes and a reaction involving fever, skin peeling, and organ involvement — have been reported with modafinil, more commonly in children.[9]
Psychological risks
Anxiety and nervousness are documented at higher doses.[6] A systematic review found no predominance of adverse mood changes when modafinil was used for cognitive enhancement in healthy individuals.[23] Caution is warranted for anyone with a history of psychosis or mania, given dopaminergic stimulation.inferred
Tolerance and dependence
Tolerance develops with prolonged use, driven by dopamine receptor changes from sustained DAT occupancy.[1] Physical dependence is rare — few confirmed cases appear in the published literature.[5] Cross-tolerance is confirmed with modafinil and armodafinil.
Psychological reliance is possible, but adrafinil does not sustain robust self-administration in animal models.[5] Lower addiction risk compared to amphetamines reflects slower dopamine elevation, absence of direct dopamine release, and selective arousal without strong reward signaling.[5][19] Fatigue rebound effect after stopping chronic use has been reported; no severe withdrawal has been documented.citation needed
Drug Interactions
The most critical interaction involves hormonal contraceptives. Modafinil activates a liver enzyme (CYP3A4) that accelerates the breakdown of hormonal contraceptives, reducing their effectiveness.[24] Alternative or backup contraception is required during adrafinil use and for at least one month after stopping.
Modafinil also inhibits a second liver enzyme (CYP2C19), slowing the breakdown of certain medications and raising their blood levels — including phenytoin, diazepam, omeprazole, propranolol, and some antidepressants.[25][21] Combining with other stimulants (amphetamine, cocaine, methylphenidate) adds cardiovascular strain through overlapping dopamine effects.[26] No published data exist for combinations with monoamine oxidase inhibitors, but theoretical concern for increased toxicity exists.safety citation needed
Contraindications
7 knownLiver impairment is the most significant contraindication specific to adrafinil — impaired liver function may reduce conversion to modafinil while increasing exposure to the parent compound.[21]
Known allergy to modafinil or armodafinil is an absolute contraindication, as adrafinil converts directly to modafinil.
Use in children is contraindicated due to elevated risk of severe skin reactions.[9]
History of psychosis or mania is a relative contraindication due to dopaminergic stimulation.inferred
Heart conditions warrant caution due to potential blood pressure and heart rate elevation.[6]
Hormonal contraceptive use requires alternative or backup contraception.[24]
Harm Reduction[edit]
Forms & Identification
Adrafinil circulates as a white crystalline powder, sold in capsules or loose form through online supplement retailers. It is a discontinued pharmaceutical — all available product comes from third-party chemical suppliers without pharmaceutical-grade quality control. Purity varies significantly between vendors, and mislabeling or substitution with other benzhydryl compounds is possible.
Third-party laboratory testing provides the most reliable verification of identity and purity.
Guidelines
- Start with the lowest effective dose and allow a full 2 hours before assessing effects — the prodrug conversion creates a slow onset that does not reflect final intensity
- Use only in the morning or early afternoon to avoid insomnia
- Avoid daily use — chronic dosing increases hepatic burden compared to modafinil
- Request liver enzyme testing before beginning a course of regular use and periodically thereafter
- Stay hydrated and maintain regular meals, as appetite suppression may mask hunger
- Test purchased material through a third-party laboratory when possible
Set & Setting
Adrafinil's delayed onset (1–2 hours) and long duration make timing critical. Morning dosing avoids interference with sleep. The prodrug conversion creates a deceptively slow start — first-time users sometimes redose prematurely, believing the initial dose was ineffective, and experience excessive stimulation hours later.
A calm, productive environment suits the compound's quiet alertness profile.
Aftercare & integration. Adrafinil's long duration means residual stimulation can persist into the evening. Prioritize sleep recovery: dim lighting, avoid screens, and allow a 2–3 hour wind-down before attempting sleep. Eat a full meal if appetite was suppressed during the day. Avoid caffeine in the afternoon and evening following use.
After regular use, fatigue rebound effect is common for several days. Allow natural sleep-wake cycles to re-establish before resuming any stimulant. If use was motivated by chronic fatigue or cognitive difficulty, consider whether the underlying cause warrants medical evaluation rather than continued self-medication.
Recovery & Support
Physical dependence on adrafinil is rare, but psychological reliance on wakefulness-promoting agents can develop — particularly when use masks underlying sleep disorders, depression, or chronic fatigue. If adrafinil use has become routine to function normally, this pattern warrants honest assessment.
A healthcare provider can evaluate whether an underlying condition is driving the need for cognitive enhancement. Gradual tapering rather than abrupt cessation minimizes fatigue rebound. Support resources include sleep medicine clinics and, where use has become compulsive, addiction support services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Adrafinil emergencies are rare but recognizable.
Signs that require immediate help:
- Chest pain, rapid or irregular heartbeat
- Severe allergic reaction: skin rash, swelling of the face or throat, difficulty breathing
- Uncontrollable involuntary movements, especially of the face or jaw
- Seizure or loss of consciousness
- Severe anxiety or paranoid thinking that does not respond to reassurance
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Keep the person calm, seated, and in a quiet environment
- 3. Do not induce vomiting
- 4. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher: name the substance (adrafinil), the amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Adrafinil occupies an unusual position in drug law: a discontinued pharmaceutical whose active metabolite (modafinil) is controlled or prescription-only in most countries, while adrafinil itself remains unscheduled in several major markets.[4][11]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled, unregulated | Not FDA-approved; not a DEA-controlled substance; legal to possess and privately import[4] |
| United Kingdom | Not specifically scheduled | Falls under Psychoactive Substances Act 2016, restricting commercial supply but not personal possession[27] |
| France | Discontinued pharmaceutical | Olmifon marketed 1985–2011; voluntarily withdrawn by Cephalon[2][3] |
| Canada | Unregulated | Legal as research chemical; can be purchased and privately imported[27] |
| Australia | Prescription required | Not freely available over the counter[27] |
| Germany | Available as research chemical | Not approved as pharmaceutical; no prescription required[28] |
| New Zealand | Prescription required | Regulated as prescription medicine[27] |
| WADA (sport) | Prohibited in-competition | S6 Stimulants category since 2004; metabolizes to modafinil (also prohibited)[13][14] |
Legal status varies by jurisdiction and can change without notice. In the United States, the Federal Analogue Act could theoretically apply to adrafinil as a structural analog of modafinil (Schedule IV), but enforcement under this provision has not been documented.citation needed This information is not legal advice — verify current local regulations before purchasing or possessing adrafinil.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- 10.5 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- modafinil · armodafinil · benzhydryl class nootropics
Toxicity
Acute toxicity is low. The mouse oral LD₅₀ is 1,950 mg/kg.[7] No human overdose case reports have been published.
Common adverse effects (derived from modafinil clinical data) include headache (up to 34% in trials), nausea, nervousness, insomnia, diarrhea, dry mouth, and elevated blood pressure and heart rate.[6]
Heart and circulation
Adrafinil and modafinil show lower cardiovascular stimulant risk than cocaine, desipramine, and bupropion at equivalent doses in animal models.[28] Elevated heart rate and blood pressure are nonetheless documented at clinical doses of modafinil.[6]
Liver
Modafinil is rated "unlikely cause of clinically apparent liver injury" by LiverTox. In a US study of 899 drug-induced liver injury cases, none were attributed to modafinil. Liver enzyme elevations exceeding three times the upper limit of normal occurred in less than 1% of patients in safety trials.[9]
No primary literature documents adrafinil-specific liver injury. However, adrafinil requires additional hepatic processing compared to taking modafinil directly, raising a theoretical concern for greater liver burden with chronic use. Liver enzyme monitoring is recommended for chronic adrafinil use.safety citation needed
Movement disorders
A single case report documents persistent involuntary facial movements (orofacial dyskinesia) following chronic adrafinil use. The movements did not resolve after four months of discontinuation and required treatment with tetrabenazine, a dopamine-depleting drug.[8] Neurologically vulnerable patients — including elderly and post-stroke individuals — appear at higher risk for movement-related adverse effects.citation needed
Skin reactions
Rare severe skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with modafinil, more commonly in children.[9]
Psychological risks
Anxiety and nervousness are documented adverse effects of modafinil, particularly at higher doses.[6] A systematic review found no preponderance of adverse mood changes when modafinil was used for cognitive enhancement in healthy subjects.[29]
Modafinil carries caution for individuals with a history of psychosis or mania, given its dopaminergic and adrenergic stimulation. No psychiatric case reports specific to adrafinil have been identified.inferred
Tolerance and dependence
Tolerance develops with prolonged use. No controlled human studies have characterized its rate for adrafinil specifically. The mechanism is presumed to involve dopamine receptor changes secondary to sustained DAT occupancy.[1] Cross-tolerance is confirmed with modafinil and armodafinil.
Physical dependence is rare. Few confirmed cases of modafinil dependence appear in the published literature.[5] Psychological dependence is possible, but modafinil does not sustain robust self-administration in animal models.[5]
The lower abuse liability relative to amphetamines is attributed to slower DAT occupancy kinetics, absence of direct monoamine release, and selective arousal without robust reward signaling.[5][26]
No controlled withdrawal studies exist. Fatigue rebound effect following cessation of chronic use has been reported anecdotally. No severe withdrawal syndrome has been documented.citation needed
Drug Interactions
Adrafinil's interaction profile is mediated through modafinil.
The most critical interaction involves CYP3A4 induction. Modafinil induces CYP3A4, reducing the effectiveness of drugs processed by this enzyme. This includes hormonal contraceptives — alternative or backup contraception is required during adrafinil use and for at least one month after stopping.[30]
Modafinil also inhibits CYP2C19, potentially increasing blood levels of drugs processed by this enzyme, including phenytoin, diazepam, omeprazole, propranolol, and certain tricyclic antidepressants.[31][20]
Concurrent use with other stimulants (amphetamine, cocaine, methylphenidate) produces additive effects through overlapping dopamine mechanisms, with potential for increased cardiovascular strain. A clinical study found no significant pharmacokinetic interaction between modafinil and methylphenidate specifically.[32]
The combination of modafinil with citalopram (an SSRI) showed increased reinforcing properties in animal models.[33]
No published interaction data exist for combinations with monoamine oxidase inhibitors, lithium, or anticonvulsants. Theoretical concern exists for increased toxicity with MAOI combinations based on mechanism.safety citation needed
Contraindications
7 knownLiver impairment is the most significant contraindication specific to adrafinil. Impaired liver function may reduce conversion to modafinil while increasing parent compound exposure.[20]
Known allergy to modafinil or armodafinil is an absolute contraindication, as adrafinil converts to modafinil.
Use in children is contraindicated due to risk of serious skin reactions.[9]
History of psychosis or mania is a relative contraindication due to dopaminergic stimulation.inferred
Heart conditions warrant caution due to potential blood pressure and heart rate elevation.[6]
Hormonal contraceptive use requires mitigation through alternative or backup contraception.[30]
Harm Reduction[edit]
Forms & Identification
Adrafinil circulates primarily as a white crystalline powder sold in capsules or loose powder form through online supplement retailers. Since it is a discontinued pharmaceutical with no current manufacturer, all available product is produced by third-party chemical suppliers without pharmaceutical-grade quality control. Purity can vary significantly between vendors, and mislabeling or substitution with other benzhydryl compounds is possible. Third-party testing through independent laboratories provides the most reliable verification of identity and purity.
Guidelines
- Start with the lowest effective dose and allow a full 2 hours before assessing effects — the prodrug conversion creates a slow onset that does not reflect final intensity
- Use only in the morning or early afternoon to avoid insomnia
- Avoid daily use — chronic dosing increases hepatic burden compared to modafinil
- Request liver enzyme testing before beginning a course of regular use and periodically thereafter
- Stay hydrated and maintain regular meals, as appetite suppression may mask hunger
- Test purchased material through a third-party laboratory when possible
Set & Setting
Adrafinil's delayed onset (1–2 hours) and long duration make timing important. Morning dosing avoids interference with sleep. The effects are subtle compared to traditional stimulants — first-time users sometimes redose prematurely, believing the initial dose was ineffective, leading to excessive stimulation hours later. A calm, productive environment suits the compound's quiet alertness profile.
Aftercare & integration. Adrafinil's long duration means residual stimulation can persist into evening hours. Prioritize sleep recovery: dim lighting, avoid screens, and allow a wind-down period of 2–3 hours before attempting sleep. Eat a full meal if appetite was suppressed during the day. Caffeine should be avoided in the afternoon and evening following adrafinil use.
After regular use, fatigue rebound effect is common for several days. Allow natural sleep–wake cycles to re-establish before resuming any stimulant. If use was motivated by chronic fatigue or cognitive difficulty, consider whether the underlying cause warrants medical evaluation rather than continued self-medication.
Recovery & Support
Physical dependence on adrafinil is rare, but psychological reliance on wakefulness-promoting agents can develop — particularly when use masks underlying sleep disorders, depression, or chronic fatigue. If adrafinil use has become routine to function normally, this pattern warrants honest assessment.
A healthcare provider can evaluate whether an underlying condition is driving the need for cognitive enhancement. For individuals seeking to reduce or stop use, gradual tapering rather than abrupt cessation minimizes fatigue rebound. Support resources include sleep medicine clinics and, where substance use has become compulsive, addiction support services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Adrafinil emergencies are rare but recognizable.
Signs that require immediate help:
- Chest pain, rapid or irregular heartbeat
- Severe allergic reaction: skin rash, swelling of the face or throat, difficulty breathing
- Uncontrollable involuntary movements, especially of the face or jaw
- Seizure or loss of consciousness
- Severe anxiety or paranoid thinking that does not respond to reassurance
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Keep the person calm, seated, and in a quiet environment
- 3. Do not induce vomiting
- 4. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher: name the substance (adrafinil), the amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Adrafinil occupies an unusual position in international drug law: a discontinued pharmaceutical whose active metabolite (modafinil) is a controlled or prescription substance in most jurisdictions, while adrafinil itself remains unscheduled in several major markets. This regulatory asymmetry has facilitated its re-emergence as an over-the-counter nootropic supplement.[4][11]
Both adrafinil and modafinil are prohibited in competitive sport under the World Anti-Doping Agency (WADA) prohibited list, classified under S6 (Stimulants), in-competition only, since 2004.[13][14]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled, unregulated | Not FDA-approved; not a DEA-controlled substance; legal to possess and privately import[4] |
| United Kingdom | Not specifically scheduled | Falls under Psychoactive Substances Act 2016, restricting commercial supply but not personal possession[34] |
| France | Discontinued pharmaceutical | Olmifon marketed 1985–2011; voluntarily withdrawn by Cephalon[2][3] |
| Canada | Unregulated | Legal as research chemical; can be purchased and privately imported[34] |
| Australia | Prescription required | Not freely available over the counter[34] |
| Germany | Available as research chemical | Not approved as pharmaceutical; no prescription required[35] |
| New Zealand | Prescription required | Regulated as prescription medicine[34] |
| WADA (sport) | Prohibited in-competition | S6 Stimulants category since 2004; metabolizes to modafinil (also prohibited)[13][14] |
The Federal Analogue Act (21 U.S.C. § 813) could theoretically apply to adrafinil as a structural and functional analogue of modafinil (Schedule IV), but enforcement under this provision has not been documented. The Act's requirement that a substance be "intended for human consumption" complicates its application to products marketed as "research chemicals" or "dietary supplements".citation needed
Frequently asked questions
What is Adrafinil?
Adrafinil is a synthetic eugeroic stimulant of the benzhydryl class and a prodrug of modafinil, first developed in France in 1974. It acts indirectly via DAT blockade following hepatic conversion, producing sustained wakefulness with low abuse liability.
How long does Adrafinil last?
Total duration by route of administration — Oral: 6 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Adrafinil?
Psychedex publishes a dosage table for Adrafinil on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Adrafinil?
The highest-severity documented interactions for Adrafinil: Ibogaine (Lethal), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antipsychotics (Dangerous), Benzodiazepines, Barbiturates (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Adrafinil addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Adrafinil: tolerance builds slow; full reset takes 10.5 days; cross-tolerance develops with modafinil, armodafinil, benzhydryl class nootropics. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcVolkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. — JAMA doi:10.1001/jama.2009.351
- [2]
- [3]
- [4]
- [5]
- [6]
references
- [1] ^abcVolkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. — JAMA doi:10.1001/jama.2009.351
- [2]
- [3]
- [4]
- [5]
- [6]